However , key secondary endpoints were met : the mean @ h C-peptide AUC was significantly higher ( mean increase of @ nmol/L -LSB- @ % CI -@ to @ -RSB- vs decrease of -@ nmol/L -LSB- -@ to -@ -RSB- ; p = @ ) , and daily insulin use ( @ units per kg per day for placebo vs @ units per kg per day for alefacept ; p = @ ) and the rate of hypoglycaemic events ( mean of @ events per person per year for alefacept vs @ events for placebo ; p < @ ) was significantly lower at @ months in the alefacept group than in the placebo group .